Will a Band-Aid Be Enough for J&J's Latest Recall?

Check that bottle of Motrin Infants formula before you give it to a baby.

Johnson & Johnson (NYSE: JNJ  ) recently announced a recall of around 200,000 bottles of Motrin Infants' Drops Original Berry Flavor. The problem is that some of the medicine could contain tiny pieces of plastic. J&J said that three lots of the half-ounce bottles -- with lot numbers DCB3T01, DDB4R01 and DDB4S01 -- could potentially be affected.

Thankfully, no illnesses or injuries have been reported so far, according to the company. Could the recall ultimately hurt J&J, though?

Is a Band-Aid enough?
This latest incident appears to only be a minor scratch for J&J. While 200,000 bottles might seem like a big number, it's not that large compared with past recalls. The company stated that the problem resulted from a manufacturing process at a third-party supplier.

J&J moved quickly to issue the recall. The company asked retailers to remove the affected products from store shelves. Customers who already purchased bottles of medication from the affected lots can call for a refund.

Because of the relative small scale of the recall, no reported problems, and the company's rapid response, there has been no discernible impact on J&J stock. However, yet another instance of quality issues could have some investors wondering if J&J needs more than just a symbolic Band-Aid to fix its underlying problem.

Recurring theme
So far in 2013, J&J has already recalled 32 million oral contraceptives, 3.3 million bottles of Tylenol drops, nearly 2 million blood glucose meters, 1.7 million bottles of Children's Tylenol, and 7,500 hip implants because of various quality issues. Since 2009, the company has conducted around 40 recalls.

The biggest of these occurred in 2010. J&J recalled more than 136 million over-the-counter medications including Tylenol, Motrin, and Zyrtec. This recall did take a toll on shares. It also resulted in the shutdown of J&J's McNeil business unit's primary manufacturing facility in Fort Washington, Penn.

After that big recall, Warren Buffett actually added to his position in J&J. However, following further woes -- including more recalls and litigation -- Buffett dumped most of his shares in the company. He commented in an interview that J&J had "obviously messed up in a lot of ways in the last few years."

By comparison
Buffett sold a couple of billion dollars' worth of J&J stock throughout 2012. He probably would have been better off holding on to them. J&J ended up more than 6% in 2012. Shares are up nearly 25% so far in 2013.

Despite the plethora of recalls, J&J handles them well. The company set the standard on how to deal with public relations issues related to product safety with the big Tylenol scare that occurred in 1982. Other companies appear to have learned from J&J along the way.

For example, Pfizer (NYSE: PFE  ) recalled around 1 million birth control pills in January and February 2012. Despite the negative publicity, the stock didn't suffer appreciably. Of course, the birth control pills -- Lo/Ovral-28 and generic norgestrel and ethinyl estradiol -- weren't huge revenue generators for Pfizer. Sales figures weren't high enough to even provide details on the company's SEC filings, so a negligible stock impact was to be expected.

Likewise, Novartis (NYSE: NVS  ) had a big recall of over-the-counter medications, including Excedrin and NoDoz, in January 2012. Shares fell slightly, but Novartis recovered easily. Novartis took a one-time charge of $120 million related to the recall. However, as with Pfizer, the financial hit wasn't enough to make a significant dent in the stock's performance.

Even when there aren't major negative effects, it's never good when a drugmaker has to recall its products. Doing so 40 times within a span of less than five years certainly isn't a track record to brag about -- no matter how well the recalls are handled.

However, there are no indications that the recalls from this year are affecting J&J's stock performance. Investors probably don't have any reason to be overly concerned. But if the trend continues, J&J shareholders might ask that the company apply less Band-Aids and simply be more careful.

Tired of watching your stocks stumble and bruise your bottom line? Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 22, 2013, at 5:11 PM, Davidovich wrote:

    Funny you mention "band-aid" in the title. I use band-aids ("tough strips") daily to protect my hands (I have a skin condition), but recently, the quality of the band-aids has plummeted. I have to throw out 1 out of every 2 or 3 band-aids, either for lack of adhesive, the paper won't come off, or the fabric just shreds. Sure they have introduced slick new products but that doesn't offset poor quality control. They've had this product for nearly a century -- they invented the band-aid! -- so their problems must be due to lack of attention. If this is an indication of wider issues, then JNJ has to be a sell.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2630420, ~/Articles/ArticleHandler.aspx, 9/25/2016 1:26:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****
NVS $81.48 Down -0.55 -0.67%
Novartis CAPS Rating: ****
PFE $34.26 Up +0.11 +0.32%
Pfizer CAPS Rating: ****